Clinical trials: Gardasil Vaccine
Cervical High Grade Squamous Intraepithelial Lesion
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL
Cervical cancer occurs commonly in HIV-infected women in South Africa. These women have poor response to treatment of cervical cancer precursors.
- Trial name
- NCT01928225
- Testing
- Human Papillomavirus vaccine
- Volunteers
- 180 people
- Sponsor
- University of Witwatersrand, South Africa
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant.
- Trial name
- NCT03023631
- Testing
- Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Human Papillomavirus
Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)
Primary objective: To demonstrate that administration of V503 induces non-inferior Geometric Mean Titers (GMTs) (for serum anti-HPV16 and anti-HPV18) compared to GARDASIL.
- Trial name
- NCT01304498
- Testing
- V503, GARDASIL
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Respiratory Papillomatosis (RRP)
Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*
The investigators propose the study titled "Efficacy of booster injection with Gardasil-9 vaccine on intersurgical interval (ISI) for adults with recurrent respiratory papillomatosis (RRP)".
- Trial name
- *ISI *RRP (NCT07339163)
- Testing
- GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ohio State University
Cervical Cancer
Post-Approval Safety Monitoring Program to Assess the Safety Profile of GARDASIL in China Usual Practice
This is a post-Approval Safety Monitoring Program to assess the safety profile of GARDASIL in china usual practice.
- Trial name
- NCT03659110
- Testing
- HPV 4
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Chaoyang District Centre for Disease Control and Prevention
Cervical Cancer, Hpv
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
The purpose of the study is to understand if children with liver and kidney transplants develop the antibodies from the Gardasil vaccine.
- Conditions
- Cervical Cancer, Hpv, Warts
- Trial name
- NCT01101750
- Testing
- Quadrivalent HPV for types 6, 11, 16 and 18
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Medstar Health Research Institute
Papillomavirus Infections
Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities
This project will compare the rate of regression of minimally abnormal Pap smears to normal in women who receive Gardasil to a historical control group.
- Trial name
- NCT00501189
- Testing
- human papillomavirus vaccine L1, type 6,11,16,18
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eisenhower Army Medical Center
Vaccine Administration Rates
Gardasil Administration
The purpose of the Gardasil study is to increase the rates of Gardasil vaccination at a maternal fetal Care Center. This will be done by reminding patients via text to come for follow up vaccine appointments.
- Trial name
- NCT03123419
- Testing
- Appointment reminders
- Where
- United States
- Sponsor
- St. Louis University
Anal Cancer, HIV Infections
Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men
This study will investigate the efficacy and safety of the quadrivalent vaccine (Gardasil) against the human papilloma virus (HPV) in HIV (human immunodeficiency virus) infected males.
- Trial name
- MIRB #862 (NCT00666107)
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Southern California Institute for Research and Education
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected…
- Trial name
- NCT01031069
- Testing
- GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
- Where
- 15 sites in Brazil, Estonia and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
This study will collect safety information on the use of GARDASIL™ in the Philippines.
- Trial name
- NCT01355003
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasia, Cervical Cancer
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
The overall aim of the study is to assess the effect of school-based Human Papillomavirus (HPV) vaccination by comparing type-specific HPV prevalence between vaccinated and non-vaccinated women born in 1997.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Oropharyngeal Cancer
- Trial name
- NCT02934724
- Testing
- Self sample from vagina, Self sample from the oral cavity, Questionnaire
- Where
- Norway
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Vaccine Effectiveness, HPV Vaccination
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months…
- Conditions
- Vaccine Effectiveness, HPV Vaccination, Single Dose, Immunogenicity
- Trial name
- CervALONE (NCT07256912)
- Testing
- quadrivalent HPV vaccine
- Where
- Zambia
- Volunteers
- 1,266 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
Human Papillomavirus Vaccines
Immunogenicity and Safety of One Dose of HPV Vaccine
This study will assess the immunogenicity and safety of one dose of Cecolin and one dose of Gardasil
- Trial name
- NCT06345885
- Testing
- HPV vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Human Papillomavirus
Study of Gardasil in Mid-Adult Males (MAM)
The purpose of this study is to test the effectiveness of the research study vaccine, Gardasil, in men ages 27-45 who have completed 4 years of observation in The Human Papillomavirus [HPV] infection in men (HIM) Study.
- Trial name
- NCT01432574
- Testing
- Gardasil
- Where
- 2 sites in United States, Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Vaccines, Meningococcal Vaccines
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
This is a clinical study to assess the safety, tolerance and immunogenic response to Gardasil (human papilloma virus (HPV)) and rLP2086 vaccine.
- Trial name
- NCT01461993
- Testing
- rLP2086 and Gardasil, rLP2086, Gardasil
- Where
- 87 sites in United States
- Volunteers
- 2,499 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.
- Trial name
- FUTURE II (NCT00092534)
- Testing
- Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 12,167 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Infections
GARDASIL™ Vaccine Impact in Population Study (V501-033)
This study will assess the impact of GARDASIL™ human papillomavirus (HPV) vaccine in the general female population by utilizing nationwide registry databases in the participating Nordic countries.
- Trial name
- VIP (NCT01077856)
- Volunteers
- 54,516 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
This is a China registration study. A randomized, double-blind, placebo-controlled immunogenicity and safety study in Chinese female participants aged 9 to 45 years and male participants aged 9 to 15 years.
- Trial name
- NCT00496626
- Testing
- Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Anogenital Human Papilloma Virus Infection, Condyloma Acuminata
Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
This is a study of V501 [quadrivalent Human Papillomavirus (HPV) (Type 6, 11, 16 and 18) L1 virus-like particle (VLP) vaccine] in healthy Japanese boys. This study will consist of two periods.
- Trial name
- NCT02576054
- Testing
- V501
- Where
- Japan
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC